Precision BioSciences (NASDAQ:DTIL) reported a sharp swing to profitability in its final quarter of 2025, a result primarily driven by the recognition of deferred revenue from its heavyweight partnerships in the genome-editing space.
The Durham, North Carolina-based biotechnology firm posted net income of $20.1 million, or $1.05 per share, for the fourth quarter.
On an adjusted basis, excluding one-time gains and non-cash items, earnings stood at $0.36 per share, significantly outperforming the consensus loss predicted by analysts.
The quarterly surge was fueled by $34.2 million in revenue, largely attributed to milestones within its ARCUS platform collaborations, including the conclusion of a hemoglobinopathy program with Novartis and licensing activity with Imugene.
Despite the strong finish to the year, the full-year 2025 results reflected the high costs of clinical-stage drug development.
Precision reported an annual loss of $45.7 million on total revenue of $34.3 million—highlighting that almost the entirety of the year's revenue was realized in the final three months.
The company’s strategic focus remains on its in vivo gene-editing pipeline.
Management highlighted the continued advancement of PBGENE-HBV, its potentially curative treatment for chronic Hepatitis B, which provided "first-of-its-kind" molecular evidence of viral DNA editing in clinical trials late last year.
Additionally, the company recently received FDA Fast Track Designation for its Duchenne Muscular Dystrophy (DMD) program, with initial patient data expected by the end of 2026.
Crucially for investors, the company strengthened its balance sheet via a $75 million capital raise in November 2025.
Precision now expects its current cash position to fund operations through the end of 2028, providing a multi-year buffer to reach critical data readouts for its lead clinical programs.